Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14040320 | 1.00 | MAPT (0.48) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL11809295 | 0.98 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL28242676 | 0.86 | CYP4Z1 (0.48) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL13282569 | 0.84 | CA1 (0.54) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| Ethyl Acetate SCHEMBL28243543 | 0.84 | ALDH1A1 (0.40) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL28242757 | 0.83 | MAPT (0.46) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL28242729 | 0.83 | NPC1 (0.58) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL28243545 | 0.83 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL654318 | 0.83 | LMNA (0.50) | MAPTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL654319 | 0.83 | LMNA (0.50) | MAPTALDH1A1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108586404-A | A kind of synthetic method of N- aryl naphtho- furanone imine compound | 湖南大学 | 2018-09-28 | — | — | CN | claimed |
| CN-108586404-A | A kind of synthetic method of N- aryl naphtho- furanone imine compound | 湖南大学 | 2018-09-28 | — | — | CN | disclosed |
| US-20100152446-A1 | Piperidine Derivatives | NERRE THERAPEUTICS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-7652012-B2 | Orvepitant maleate; potent and specific antagonists of tachykinins, including substance P and other neurokinins; anxioltic and antidepressant | GLAXO GROUP LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7482365-B2 | 4-(2,2-Dimethyl-propylamino)-2-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide; specific antagonists of tachykinins receptor: substance P and neurokinins (NK1); antidepressant, anxiolytic agent; serotonin receptor inhibitor | GLAXO GROUP LIMITED (GB) | 2009-01-27 | — | — | US | disclosed |
| US-20070099914-A1 | Piperidine Derivatives | NERRE THERAPEUTICS LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
| US-7189713-B2 | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099914-A1 | Piperidine Derivatives | PTGES2, NFKBIA, PTGS2 | MAPT 2632/4885ALDH1A1 332/4885MEN1 4813/4885 |
| US-20100152446-A1 | Piperidine Derivatives | NPSR1, NPY5R, NPY4R | MAPT 4616/4885ALDH1A1 3922/4885MEN1 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.